Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3% – Should You Sell?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares dropped 6.3% during trading on Monday . The stock traded as low as $4.68 and last traded at $4.6650. Approximately 185,210 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 2,549,399 shares. The stock had previously closed at $4.98.

Analyst Upgrades and Downgrades

TSHA has been the subject of several research reports. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a research note on Friday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, JMP Securities set a $8.00 price target on Taysha Gene Therapies in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.67.

Taysha Gene Therapies Stock Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The business has a 50-day simple moving average of $4.93 and a 200-day simple moving average of $3.88. The firm has a market capitalization of $1.33 billion, a PE ratio of -14.73 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock in a transaction on Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the sale, the insider owned 1,006,439 shares of the company’s stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marex Group plc purchased a new stake in Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at $31,000. ST Germain D J Co. Inc. increased its position in shares of Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares in the last quarter. May Hill Capital LLC acquired a new stake in shares of Taysha Gene Therapies in the second quarter valued at approximately $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies during the 3rd quarter worth $40,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.